Mod GRF 1-29

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

This analog has no FDA-approved drug application. FDA's Category 2 Bulk Drug Substances List entry for 'CJC-1295' does not appear to distinguish between the DAC and no-DAC forms by name, so the same restricted-compounding posture is treated as applying here pending clarification. As of April 23, 2026, HHS/FDA signaled removal of approximately 14 of 19 Category 2 peptides; CJC-1295 (either form) is not among the substances formally nominated for the July 23-24, 2026 PCAC 503A bulks review, and compounding status remains uncertain. Possession and use outside of research or licensed compounding channels may violate the FD&C Act.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit)

Transparent blend · bci-1.0 · never paid-placement

Primary name

Mod GRF 1-29

Origin

A 29-residue analog of endogenous GHRH(1-29) carrying the same stabilizing amino-acid substitutions used in CJC-1295, but without the C-terminal drug affinity complex (DAC) maleimide-lysine extension that enables covalent albumin binding. Commonly marketed and discussed as 'Mod GRF 1-29' or 'CJC-1295 without DAC.' PubChem CID 56841945 / CAS 863288-34-0 (formula C152H252N44O42) is a chemically distinct, lighter molecule than the DAC-conjugated CJC-1295 (CID 91971820 / CAS 446262-90-4, formula C165H269N47O46) -- see cjc-1295 for the DAC variant.

Registry IDs

PubChem CID

56841945

CAS

863288-34-0

InChIKey

XOZMWINMZMMOBR-HRDSVTNWSA-N

Molecular formula

C152H252N44O42

Molar mass

3367.9 g/mol

Monoisotopic

3365.8935782 Da

InChIKey

XOZMWINMZMMOBR-HRDSVTNWSA-N

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH
• Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs
• A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule

Pharmacokinetics (ADME)

Half-life

Not reported in peer-reviewed human studies of this specific compound (PMID 42395176). Frequently cited as ~30 minutes in vendor/community material by analogy to unmodified GHRH(1-29) pharmacokinetics, but this figure has not been directly measured for this compound in a peer-reviewed human trial and is not independently verified here.

Clearance

Not characterized in peer-reviewed human literature

PK–PD note: No dedicated human PK/PD trial has been published for this compound. All effect claims for this specific molecule are extrapolated from related GHRH(1-29) analogs, per PMID 42395176 -- contrast with t…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No dedicated human safety trial exists for this specific compound; the class-level theoretical concerns applicable to GHRH-receptor agonists (fluid retention, transient injection-site reactions, potential insulin resistance from sustained GH elevation, and, at supraphysiological …

WADA status

Prohibited -- WADA 2026 Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which covers GHRH and its analogues/mim…

Dominant research route: SC (subcutaneous injection) by convention with the wider GHRH(1-29) analog class; no controlled no-DAC (Mod GRF 1-29) human or animal PK trial has been identified — the form is described as essentially uncharacterised in peer-reviewed human literature (PMID 42395176).

No controlled human or animal pharmacokinetic trial identified for the no-DAC (Mod GRF 1-29) form. A 2026 narrative review (PMID 42395176) states the no-DAC form is 'essentially uncharacterised in the peer-reviewed human literature,' with no controlled human trials.

Bioavailability: No peer-reviewed pharmacokinetic data exists for the no-DAC form. It is understood to be short-acting relative to the DAC-conjugated form (which the DAC form's own trials put at a 5.8-8.1 day half-life via albumin binding), but a specific no-DAC half-life or bioavailability figure is NOT established in the peer-reviewed literature — no number is asserted here.

A commonly-repeated '~30 minute half-life' figure for the no-DAC form is not supported by peer-reviewed literature and is deliberately NOT asserted here (fail-closed per PMID 42395176's own characterization of this form as uncharacterised). Oral route not assessed for this variant.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

p25 $8.00 · median $8.20 · p75 $8.40 · 1 researched vendor

Legit, COA-backed band: $7.80–$8.60/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$78

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

A CJC-1295 (Mod GRF 1-29) no-DAC lot independently tested by Janoshik Analytical reported 99.624% purity of actual content, but only 4.57 mg vs a 10 mg label claim — a significant underdose (~54% below labeled potency).

Independent labs cited for this compound

One recall found that names 'CJC-1295 Injectable' without specifying formulation: FDA Class II recall of CJC-1295 Injectable by Thrive Health Solutions (Englewood, CO), 60 pre-filled syringes across two lots, voluntarily initiated May 21, 2025, FDA-classified June 20, 2025, reason: lack of assurance of sterility.

Buyer red-flag checklist

• CJC-1295 is not FDA-approved; no approved 503A bulk substance listing as of 2024 PCAC review.
• FDA flagged CJC-1295 for reports of elevated heart rate and cardiac effects, plus concerns about peptide impurities and immune reactions.
• WADA Prohibited List S2.2.4 — banned at all times, in and out of competition.
• Class II recall of compounded CJC-1295 injectable due to lack of sterility assurance (Thrive Health Solutions, 2025); formulation not specified in the recall notice.
• Grey-market 'research use only' marketing under active FDA enforcement; warning letters issued to multiple peptide vendors in late 2024/early 2025.
• Independent aggregate testing (Finnrick) flagged a major vendor's CJC-1295 for quality/underdosing failures across 10 samples (formulation unspecified).
• FDA PCAC briefing noted no Certificate of Analysis was submitted for CJC-1295 (free base) in 503A bulks nominations.
• Independent Janoshik Analytical testing of a no-DAC (Mod GRF 1-29) CJC-1295 lot found significant underdosing: 4.57 mg actual vs 10 mg labeled content.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: A Janoshik Analytical-tested no-DAC (Mod GRF 1-29) lot showed significant underdosing (4.57 mg actual vs 10 mg labeled). Separately, independent aggregate testing (Finnrick, 10 samples of one major vendor's CJC-1295, Dec 2024-Mar 2026) flagged substantial underdosing/quality failure across the broader CJC-1295 market (formulation unspecified). A specific prevalence fraction cannot be computed from available public data.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') authorizes DWPE of unapproved-drug peptide imports at the border. Last revised May 19, 2026. A 'research use only' label does not create an importation exemption; FDA evaluates actual marketed/intended use.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in and out of competition) under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), subcategory S2.2.4 Growth Hormone Releasing Factors. CJC-1295 is named explicitly alongside CJC-1293, sermorelin, and tesamorelin as a GHRH analogue. Both DAC and no-DAC versions are banned.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-reported unverified anecdotes
• Vendor-affiliated content / affiliate links present in aggregator pages
• Survivorship bias toward positive responders
• Conflation of effects with co-administered Ipamorelin
• DAC vs no-DAC confusion inflates adverse-event attribution
• This sample reflects shared CJC-1295-family discussion (Reddit/YouTube), not measured separately for the no-DAC form — the underlying social listening did not distinguish DAC vs no-DAC

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date. Approximately 2 articles are indexed (literature last scanned 2026-07-16). US regulatory status: Not FDA-approved; RUO / restricted compounding. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet